KORU Medical SystemsKRMD
KRMD
About: KORU Medical Systems Inc is a developer and manufacturer of medical devices and supplies. It focuses on mechanical infusion products, the FREEDOM Infusion Systems. Its primary products include the Freedom Integrated Infusion System: the FREEDOM60 and FreedomEdge Syringe Drivers, Precision Flow Rate Tubing, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. It is a manufacturer of subcutaneous infusion devices that deliver life-saving immunoglobulin therapies to patients with chronic illnesses such as Primary Immunodeficiencies (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
Employees: 80
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
280% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 5
115% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 13
22% more funds holding
Funds holding: 64 [Q4 2024] → 78 (+14) [Q1 2025]
0.44% more ownership
Funds ownership: 37.48% [Q4 2024] → 37.92% (+0.44%) [Q1 2025]
33% less capital invested
Capital invested by funds: $66.2M [Q4 2024] → $44.3M (-$21.9M) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$3.50
8%
upside
Avg. target
$3.50
8%
upside
High target
$3.50
8%
upside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
Piper Sandler Jason Bednar | 8%upside $3.50 | Neutral Maintained | 8 May 2025 |
Financial journalist opinion
Neutral
Business Wire
3 days ago
KORU Medical Systems to Join Russell 3000® and Russell 2000® Indexes
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company is set to join the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the Russell indexes annual reconstitution, effective after the US.
Neutral
Seeking Alpha
1 month ago
KORU Medical Systems, Inc. (KRMD) Q1 2025 Earnings Call Transcript
KORU Medical Systems, Inc. (NASDAQ:KRMD ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Louisa Smith - Investor Relations Linda Tharby - Chief Executive Officer and President Tom Adams - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Caitlin Cronin - Canaccord Genuity Chase Knickerbocker - Craig-Hallum Jason Bednar - Piper Sandler Anderson Schock - B. Riley Securities Operator Greetings, and welcome to KORU Medical Systems First Quarter 2025 Earnings Conference Call.
Negative
Zacks Investment Research
1 month ago
KORU Medical Systems Inc. (KRMD) Reports Q1 Loss, Tops Revenue Estimates
KORU Medical Systems Inc. (KRMD) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to loss of $0.02 per share a year ago.
Neutral
Business Wire
1 month ago
KORU Medical Systems Announces Record Q1 2025 Financial Results and Raises 2025 Revenue Guidance
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights First quarter 2025 net revenues of $9.6 million, an 18% increase over the prior year period Core business (Domestic an.
Neutral
Seeking Alpha
3 months ago
KORU Medical Systems, Inc. (KRMD) Q4 2024 Earnings Call Transcript
KORU Medical Systems, Inc. (NASDAQ:KRMD ) Q4 2024 Earnings Conference Call March 12, 2025 4:30 PM ET Company Participants Louisa Smith - Investor Relations Linda Tharby - Chief Executive Officer and President Tom Adams - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig Hallum Capital Group Frank Takkinen - Lake Street Capital Markets Jason Bednar - Piper Sandler Anderson Shack - B. Riley Securities Michaela Smith - Canaccord Operator Greetings.
Neutral
Business Wire
3 months ago
KORU Medical Systems Announces Fourth Quarter and Full Year 2024 Financial Results With Record Revenues and Gross Profit; Issues Full Year 2025 Guidance
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024. The Company also issued guidance for the full year 2025. Recent Highlights Fourth quarter 2024 net revenues of $8.8 mi.
Neutral
Business Wire
3 months ago
KORU Medical Systems to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report fourth quarter and full year 2024 financial results on Wednesday, March 12, 2025. KORU Medical's management will host a conference call and webcast at 4:30 p.m. ET that.
Positive
Seeking Alpha
4 months ago
KORU Medical Systems Has A Long Runway
KORU Medical Systems' stock has surged 60% since November, driven by the success of its FREEDOM System for subcutaneous immunoglobulin delivery. The SCIg market is growing rapidly, with KORU outperforming competitors by capturing market share and benefiting from trends like prefilled syringes. Strong international growth, new therapies, and product innovations are key drivers, with significant revenue from recurring patients and promising future launches.
Neutral
Business Wire
4 months ago
KORU Medical Systems Announces Agreement for Next-Generation Subcutaneous Immunoglobulin Infusion System
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced the signing of an agreement with a global pharmaceutical company. The agreement is intended for KORU Medical to develop and seek regulatory clearance for a next-generation subcutaneous immunogl.
Neutral
Business Wire
4 months ago
KORU Medical Systems Announces Phase III Clinical Trial Collaboration for a New Drug Indication in Nephrology
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced a collaboration with a global pharmaceutical manufacturer on a Phase III clinical trial for an expanded indication of a commercialized drug therapy. The expanded indication is intended to treat a rar.
Charts implemented using Lightweight Charts™